DAWN
Income statement / Annual
Last year (2023), Day One Biopharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Day One Biopharmaceuticals, Inc.'s net income was -$188.92 M.
See Day One Biopharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$383,000.00 |
$531,000.00 |
$199,000.00 |
$155,000.00 |
$0.00 |
| Gross Profit |
-$383,000.00 |
-$531,000.00 |
-$199,000.00 |
-$155,000.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$130.52 M
|
$85.62 M
|
$43.58 M
|
$9.10 M
|
$13.90 M
|
| General & Administrative
Expenses |
$75.54 M
|
$61.29 M
|
$29.16 M
|
$4.68 M
|
$1.01 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$75.54 M
|
$61.29 M
|
$29.16 M
|
$4.68 M
|
$1.01 M
|
| Other Expenses |
$1.00 |
-$18,000.00 |
-$15,000.00 |
-$31,000.00 |
-$2,000.00 |
| Operating Expenses |
$206.06 M |
$146.91 M |
$72.74 M |
$13.78 M |
$14.91 M |
| Cost And Expenses |
$206.06 M |
$146.91 M |
$72.74 M |
$13.78 M |
$14.91 M |
| Interest Income |
$17.19 M |
$4.75 M |
$4,000.00 |
$30.00 |
$2,077.00 |
| Interest Expense |
$0.00 |
$4.75 M |
$4,000.00 |
$30,000.00 |
$2.08 M |
| Depreciation &
Amortization |
$36,000.00
|
$531,000.00
|
$199,000.00
|
$155,000.00
|
$14.91 M
|
| EBITDA |
-$206.06 M
|
-$141.65 M
|
-$72.56 M
|
-$43.66 M
|
-$2,000.00
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$17.15 M
|
$4.73 M
|
-$11,000.00
|
-$30.06 M
|
-$2.08 M
|
| Income Before Tax |
-$188.92 M |
-$142.18 M |
-$72.75 M |
-$43.84 M |
-$16.98 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$10.01 M |
-$2.31 M |
-$3.34 M |
-$2.27 M |
| Net Income |
-$188.92 M |
-$132.18 M |
-$70.44 M |
-$40.51 M |
-$14.71 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
| EPS |
-2.37 |
-2.02 |
-1.14 |
-0.65 |
-0.24 |
| EPS Diluted |
-2.37 |
-2.02 |
-1.14 |
-0.65 |
-0.24 |
| Weighted Average Shares
Out |
$79.77 M
|
$65.47 M
|
$61.95 M
|
$61.93 M
|
$61.93 M
|
| Weighted Average Shares
Out Diluted |
$79.77 M
|
$65.47 M
|
$61.95 M
|
$61.93 M
|
$61.93 M
|
| Link |
|
|
|
|
|
